These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 22120961

  • 1. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
    Morizane C, Okusaka T, Ueno H, Kondo S, Ikeda M, Furuse J, Shinichi O, Nakachi K, Mitsunaga S, Kojima Y, Suzuki E, Ueno M, Yamaguchi T.
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):957-64. PubMed ID: 22120961
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
    Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J, Furuse J, Ishii H, Nagase M, Nakachi K.
    Oncology; 2005 Apr; 69(5):421-7. PubMed ID: 16319514
    [Abstract] [Full Text] [Related]

  • 6. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer.
    Nakai Y, Isayama H, Saito K, Sasaki T, Takahara N, Hamada T, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D, Kogure H, Yamamoto N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K.
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):911-5. PubMed ID: 25143299
    [Abstract] [Full Text] [Related]

  • 7. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
    Arima S, Shimizu K, Okamoto T, Toki M, Suzuki Y, Okano N, Naruge D, Kawai K, Kobayashi T, Kasuga A, Kitamura H, Takasu A, Nagashima F, Sugiyama M, Furuse J.
    Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E.
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):313-9. PubMed ID: 18398614
    [Abstract] [Full Text] [Related]

  • 9. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
    Shoji H, Morizane C, Sakamoto Y, Kondo S, Ueno H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Ikeda M, Okusaka T.
    Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
    [Abstract] [Full Text] [Related]

  • 10. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
    Yanagimoto H, Toyokawa H, Sakai D, Wada H, Satoi S, Yamamoto T, Nagano H, Toyoda M, Ajiki T, Satake H, Tsuji A, Miyamoto A, Tsujie M, Takemura S, Yanagihara K, Ioka T.
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):461-468. PubMed ID: 29305639
    [Abstract] [Full Text] [Related]

  • 11. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T, Ueno M, Ueno H, Park JO, Chang HM, Sasahira N, Kanai M, Chung IJ, Ikeda M, Nakamori S, Mizuno N, Omuro Y, Yamaguchi T, Hara H, Sugimori K, Furuse J, Maguchi H, Furukawa M, Fukuzawa K, Kim JS, Yukisawa S, Takeuchi M, Okusaka T, Boku N, Hyodo I.
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [Abstract] [Full Text] [Related]

  • 12. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
    Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, Hanada K, Kimura Y, Maetani I, Okabe Y, Tani M, Ikeda T, Hijioka S, Watanabe R, Ohoka S, Hirose Y, Suyama M, Egawa N, Sofuni A, Ikari T, Nakajima T.
    Cancer Chemother Pharmacol; 2012 May; 69(5):1197-204. PubMed ID: 22249272
    [Abstract] [Full Text] [Related]

  • 13. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
    Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB.
    J Clin Oncol; 2009 Aug 10; 27(23):3778-85. PubMed ID: 19581537
    [Abstract] [Full Text] [Related]

  • 14. [Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer].
    Nakamura K, Yamaguchi T, Sudo K, Ishihara T, Saisho H.
    Gan To Kagaku Ryoho; 2006 Jun 10; 33 Suppl 1():219-23. PubMed ID: 16898006
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
    Watanabe A, Kida M, Miyazawa S, Iwai T, Okuwaki K, Kaneko T, Yamauchi H, Takezawa M, Imaizumi H, Koizumi W.
    World J Gastroenterol; 2015 May 21; 21(19):5979-84. PubMed ID: 26019463
    [Abstract] [Full Text] [Related]

  • 16. Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial).
    Sai S, Toyoda M, Tobimatsu K, Satake H, Yasui H, Kimbara S, Koyama T, Fujishima Y, Imamura Y, Funakoshi Y, Kiyota N, Toyama H, Kodama Y, Minami H.
    Cancer Chemother Pharmacol; 2021 Jan 21; 87(1):65-71. PubMed ID: 33098471
    [Abstract] [Full Text] [Related]

  • 17. A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer.
    Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Toda N, Tada M, Kawabe T, Omata M.
    Oncology; 2009 Jan 21; 77(5):300-3. PubMed ID: 19923869
    [Abstract] [Full Text] [Related]

  • 18. Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
    Ishiwatari H, Hayashi T, Yoshida M, Ono M, Sato T, Miyanishi K, Sato Y, Takimoto R, Kobune M, Kato J.
    Cancer Chemother Pharmacol; 2015 Apr 21; 75(4):805-12. PubMed ID: 25687990
    [Abstract] [Full Text] [Related]

  • 19. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
    Oh DY, Cha Y, Choi IS, Yoon SY, Choi IK, Kim JH, Oh SC, Kim CD, Kim JS, Bang YJ, Kim YH.
    Cancer Chemother Pharmacol; 2010 Feb 21; 65(3):527-36. PubMed ID: 19578850
    [Abstract] [Full Text] [Related]

  • 20. Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer.
    Suzuki S, Ozaki Y, Saida S, Kaji S, Koike N, Harada N, Hayashi T, Suzuki M.
    Hepatogastroenterology; 2013 Jun 21; 60(124):916-20. PubMed ID: 23478143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.